Published November 2019 | Version v1
Journal article Metadata-only

HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy

Creators

  • 1. Sinai Hospital of Baltimore, Baltimore, MD (United States)
  • 2. Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church FVA (United States)
  • 3. Peter Lee Associates, Sydney (Australia)
  • 4. Platelet and Thrombosis Research, Baltimore, MD (United States)

Description

Low high-density lipoprotein (HDL-C) and inflammation are risk factors for coronary artery disease (CAD). However, limited data are available determining the role of HDL-C sub-particles HDL2-C and HDL3-C for assessing CAD severity in patients on statin therapy.

Additional details

Identifiers

DOI
10.1016/j.carrev.2018.12.019;
PII
S1553838918306225;

Publishing Information

Journal Title
Cardiovascular Revascularization Medicine (Print)
Journal Volume
20
Journal Issue
11
Journal Page Range
p. 1001-1006
ISSN
1553-8389

INIS

Country of Publication
Netherlands
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
55052336
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARDIOVASCULAR DISEASES; CORONARIES; INFLAMMATION; LIPOPROTEINS; PATIENTS; THERAPY
Descriptors DEC
ARTERIES; BLOOD VESSELS; BODY; CARDIOVASCULAR SYSTEM; DISEASES; LIPIDS; MEDICINE; ORGANIC COMPOUNDS; ORGANS; PATHOLOGICAL CHANGES; PROTEINS; SYMPTOMS

Optional Information

Copyright
Copyright (c) 2019 Elsevier Inc. All rights reserved.